Abstract:Esophageal squamous cell carcinoma (ESCC) is a prevalent cancer with high morbidity and mortality worldwide. Radiotherapy is one major curative treatment modality for ESCC. Herein, our study aimed to investigate whether CAFs (cancer-associated fibroblasts), a main component of tumor microenvironment, were involved in mediating the development of radioresistance and further explored the mechanisms underlying CAFs-mediated radioresistance in ESCC. By primary culture, two pairs of CAFs and matched NFs (normal fibroblasts) had been successfully isolated from tumor tissues of ESCC patients and matched normal esophageal epithelial tissues, respectively. The secretion of chemokines by CAFs and matched NFs was determined by the human chemokine antibody array. The concentrations of chemokine in culture medium of CAFs, matched NFs and ESCC cells were determined by Elisa assay. The effect of CAFs-secreted chemokines on radioresistance was investigated in vitro by clonogenic survival assay, detection of DNA double-strand breaks (DSBs) and by flow cytometry analysis on cell apoptosis. By establishment of xenograft tumor models in BALB/c nude mice, the effect of CAFs on radioresistance was investigated in vivo. CAFs conferred ESCC cells KYSE-30 and KYSE-150 significant radioresistance by promoting clonogenic survival and inhibiting DSBs and cell apoptosis following radiation in comparison with their matched NFs. Mechanism studies revealed that human chemokine CXCL1 (The chemokine [C-X-C motif] ligand 1) was secreted by CAFs at a significantly higher level compared with matched NFs and ESCC cells. Inhibition of CXCL1 expression in CAFs by the human specific antibody against CXCL1 significantly reversed CAFs-mediated radioresistance by enhancing radiation-induced DSBs, and inhibiting DNA damage repair response and the activation of anti-apoptotic Mek/Erk signaling pathway. The use of CXCL1 antibody also significantly reversed CAFs-mediated radioresistance in xenograft tumor models. Further studies demonstrated that CAFs-secreted CXCL1 suppressed the expression of antioxidant enzyme SOD1 (superoxide dismutases), leading to accelerated ROS (Reactive Oxygen Species) accumulation which activated DNA damage repair response and mediated the radioresistance. Moreover, the crosstalk of CAFs and ESCC cells induced CXCL1 expression in an autocrine/paracrine signaling loop by which the radioresistance was further enhanced. Our study for the first time discovered CAFs-secreted CXCL1 as an attractive target to reverse the radioresistance of ESCC.

Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma

Fibroblast-Derived Exosomes Contribute to Chemoresistance Through Priming Cancer Stem Cells in Colorectal Cancer.

IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma

Cancer‐associated Fibroblasts Mediated Chemoresistance by a FOXO1/TGFβ1 Signaling Loop in Esophageal Squamous Cell Carcinoma

CAFs-Secreted CXCL1 Mediated Radioresistance by Regulating DNA Damage Response in an ROS-Dependent Manner in Esophageal Squamous Cell Carcinoma

Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

MicroRNA-125a-5p Enhances the Sensitivity of Esophageal Squamous Cell Carcinoma Cells to Cisplatin by Suppressing the Activation of the STAT3 Signaling Pathway

M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma

Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21

Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance

Cancer-associated Fibroblasts Attenuate Cisplatin-induced Apoptosis in Ovarian Cancer Cells by Promoting STAT3 Signaling.

Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5

CAFs-derived Exosomal miR-889-3p Might Repress M1 Macrophage Polarization to Boost ESCC Development by Regulating STAT1

Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis

Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis

Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma

Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma

Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma

TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM